Advantage Alpha Capital Partners LP Halozyme Therapeutics, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $387 Million
- Q4 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 9,033 shares of HALO stock, worth $534,301. This represents 0.11% of its overall portfolio holdings.
Number of Shares
9,033
Previous 14,738
38.71%
Holding current value
$534,301
Previous $843,000
48.87%
% of portfolio
0.11%
Previous 0.2%
Shares
5 transactions
Others Institutions Holding HALO
# of Institutions
550Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.04 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$786 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$425 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$247 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$204 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.24B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...